One hundred thousand lawsuits is certainly a formidable number, but that figure could represent only half of the number of lawsuits related to COX-2 inhibitors. Earlier this year, Pfizer voluntarily withdrew its similar medication Bextra from the market, as studies linked the use of Bextra to increased heart attack risk and to a rare skin disorder known as Stevens-Johnson Syndrome. Bextra, another drug in the family of COX-2 inhibitors, works very similarly to Vioxx, and many patients who formerly took Vioxx switched to Bextra after the former was removed from the market last fall. Given that sales of Bextra rose to near Vioxx levels before it was removed from the market, it seems likely that the number of lawsuits filed by patients who claim to have been harmed by their use of Bextra could eventually equal the number of Vioxx lawsuits.
Unless the courts consolidate them into just a few class-action suits, the 200,000 potential lawsuits stemming from problems with Bextra and Vioxx could cripple our courts for the next decade. Patients who believe that they may have been harmed through the use of either Bextra or Vioxx would be well advised to contact an attorney who specializes in pharmaceutical lawsuits as soon as possible. The wait for a resolution in court, particularly for Vioxx lawsuits, could be a very long one. Those who file quickly may get the fastest results.
Copyright 2005 by Retro Marketing.
Charles Essmeier is the owner of Retro Marketing, a firm devoted to informational Websites, including Bextra-Info.net, a site devoted to the withdrawn drug Bextra and StructuredSettlementHelp.com, a site devoted to structured settlements.